LIFELIVER Co.,Ltd

Summary

Date of Establishment 2009.09.14
Representative Name Ha Yong Kim
Employees 17 (Research Staff 12 / Management staff 5)
Paid-in Capital (Investor) 11.4 Billion KRW
Featured Products Hepatocyte isolation service / R&D Consulting
Sales (2017) 6.5 Million KRW
Major Customers LC BIO CO., LTD ,Catholic University of Korea's Industrial-Academic Cooperation Group
Company Location Headquarters : (3F, Jukjeon-dong), 2776 Younggu-daero, Suji-gu, Yongin-si, Gyeonggi-do
Research Institute : 3-1001, Seven Venture Valley Complex1 15, Pangyo-ro 228 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do
Acquisition of License 1) Venture Company certification
2) Corporate Extension Research Institute certification
3) CD8α+ LYMPHOID DENDRITIC CELL DIFFERENTIATED FROMHUMAN HEMATOPOIETIC STEM CELL AND A METHOD FORMASS-PRODUCING SAME

History

  • 2018

    Acquired by HLB Lifescience
    Starting phase 2b of bioartificial liver system at SMC

  • 2017

    Research project, Development of bioartificial liver system using cryopreservation technology,
    granted by Ministry of Commerce Industry and Energy (2.7 M USD)

  • 2016

    Research project, Development of bio-mimetic hemostat, granted by Defense Acquisition Program Administration
    License-in of HepaStem from Promethera (Belgium)

  • 2015

    Developmental orphan drug designation (MFDS)
    License-in of surgical hemostat from Inha-Utah DDS

  • 2014

    Research project, Development of peritoneal bioartificial liver system, granted by Ministry of Health and Welfare

  • 2013

    Collaboration of development of bioartificial liver system with SMC (20*20 Project)

  • 2012

    Research project, Development of bioartificial liver system granted by Ministry of Health and Welfare

  • 2011

    Research project, Establishment of human hepatocyte culture and evaluation technology, granted by MFDS

  • 2010

    Starting phase 1/2a of bioartificial liver system at SMC

  • 2009

    Company establishment
    Acquiring of R&D part of Lifecord Inc.
    Building GMP Facility for bioartifical liver system at Samsung Medical Center (SMC)
    MFDS approval of phase 1/2a of bioartifical liver system

Patent

No. Patent Number Patent Name
1 No.0429140 CD8α+ LYMPHOID DENDRITIC CELL DIFFERENTIATED FROMHUMAN HEMATOPOIETIC STEM CELL AND A METHOD FORMASS-PRODUCING SAME
2 No.0449141 METHOD FOR DIFFERENTIATING A MESENCHYMAL STEM CELLINTO NEURAL CELLS
3 No.0677054 METHOD FOR ISOLATING AND CULTURING MULTIPOTENT PROGENITOR CELLS FROM UMBILICAL CORD BLOOD AND METHOD FOR INDUCING DIFFERENTIATION THEREOF
4 No.0679729 METHOD OF CELL IMMOBILIZATION ON A SURFACE OF A CARRIER
5 No.0902781 INTEGRATED DEVICE FOR THE PREPARATION OF ASEPTIC CAPSULES
6 No.0886003 BIOARTIFICIAL LIVER SYSTEM USING BIOREACTOR PACKED WITH GEL BEADS
7 No.0527623 BIODEGRADABLE POLYMER SCAFFOLD CONTAININGEXTRACELLULAR MATRIX USED FOR ARTIFICIAL ORGANS ANDMETHOD FOR PREPARING SAME
8 No.0536478 BIODEGRADABLE COLLAGEN FILM USED FOR ARTIFICIAL ORGANSAND METHOD FOR PREPARING SAME
9 No.0616752 METHOD FOR PREPARATION OF DERMAL PAPILLA TISSUEINDUCING HAIR FOLICLE FORMATION
10 No.1227047 METHOD FOR PREPARATION OF HEPATOCYTES AND HEPATOCYTES PREPARED THEREBY
11 No.1931854 peritoneal circulation apparatus and bioartificial liver support system using the same
12 No.1664444 Biodegradable medical adhesive or sealant compositions
13 No.1480987 A serum-free solution for cryopreservation of Hepatocyte and the method of cryopreservation of Hepatocyte using the same

LSK Investment

Summary

Date of Establishment 2016.04.11
Representative Name Myung Kee Kim / Sung Chul Kim
Employees (2018) 9
Paid-in Capital (Investor) 5 Billion KRW
Featured Products a start-up / venture investment
Investment Area Healthcare : Biologics, Cosmeceuticals Diagnostics, Medical Equipment
Company Location #1401, 6, Teheran-ro 34-gil, Gangnam-gu, Seoul, Korea, 06220
Acquisition of License 1) Registration of small business start-up investment company
2) Registering employees of the private equity investment group based on the Capital Markets and the Financial Investment Industry Act.

About Us

Investment
Philosophy

Investment
Area

Sinwha Advance Co.,Ltd

Vision

Korea's leading distributor leading the on-line
and off-line drug distribution market

Company History

  • Aug

    2016

    Transferred to HLB Life Science subsidiary

  • Oct

    2011

    Selected as a management innovation type SME (Small and Medium Business Administration certified)

  • Nov

    2007

    Changed the name of Shinhwa Advance Co., Ltd.

  • Mar

    2003

    Shinhwa Palm Co., Ltd. Moved office to Shinhwa Building, Yeongdeungpo-Gu, Seoul

  • Mar

    1995

    Supplied Bundang Cha Hospital

  • Jun

    1994

    Delivery of Ajou University Hospital

  • Jan

    1991

    Established Shinhwa Farm Co., Ltd.

  • Major suppliers are Ajou University Hospital, Cha Hospital (Seoul, Bundang), and national and public hospitals
  • Sinhwa Advance Co., Ltd. is one of the leading pharmaceutical companies in Korea, including Pfizer, GSK, Novartis, Sanofi-Aventis, MSD, Astra Zeneca, Boehringer-ingelheim, BMS and other major foreign pharmaceutical companies are engaged in business activities through direct transactions.

Mission

  • 01

    Market Creation and Selection
    Strengthening internal competencies Creating new business areas. Strengthening customer ties
  • 02

    Expansion of supply of pharmaceuticals (pharmaceutical consumables)
    Discover and expand new accounts
    Online MRO Market Selection
    Manufacture and distribution of pharmaceuticals (pharmaceutical consumables)
  • 03

    On-line and off-line market stabilization
    Achieved 1 trillion sales
    Stabilization of on-line and off-line business areas

Marketing Strategy

Marketing Strategy

  • 1

    Expansion of in-hospital drugs market
  • 2

    Expansion of bidding hospital market
  • 3

    Strengthen sales of pharmacies and wholesalers

Action Plan and Expected Effect

Business Goals and Strategies

1

Strategic Tasks
  • Expansion of distribution market of pharmaceuticals and medical materials

2

Strategy Policy
  • Mutual growth in the pharmaceutical market and securing new customers
  • Income by Region, Efficiency of Logistics, Target Market
  • Strategic alliance with pharmaceutical companies and wholesalers strengthens competitiveness of items
  • Strategies to promote niche markets through our sales organization

Sinwha Advance Co.,Ltd

2nd floor, Shinbwa Building, 191 Daebang-dong, Yeongdeungpo-gu, Seoul, Korea    
TEL : +82)2-834-7971    FAX : +82)2-834-7938